ZG-126

ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM) . ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization[1].

Product Specifications

CAS Number

[3049802-32-3]

UNSPSC

12352005

Target

HDAC; VD/VDR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zg-126.html

Smiles

CCC(CC)(C1=CC=C(C=C1)C(NCCCCC(NO)=O)=O)C2=NC(C)=C(C=C2)OCC(C(C)(C)C)O

Molecular Formula

C29H43N3O5

Molecular Weight

513.67

References & Citations

[1]Sarmadi F, et al., Bifunctionality and Antitumor Efficacy of ZG-126, a Vitamin D Receptor Agonist/Histone Deacetylase Inhibitor Hybrid Molecule. J Med Chem. 2024 Jun 21.